🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Revlimid 25 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 20 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, Zelvina 5 mg hard capsules, LIBTAYO 350 mg concentrate for solution for infusion., Imnovid 4 mg hard capsules, DIPHENHYDRAMINE , Revlimid 15 mg hard capsules, MONTELUKAST , JAMP Pomalidomide, PARACETAMOL , Revlimid 20 mg hard capsules, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Revlimid 25 mg hard cap

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  2. Revlimid 25 mg hard capsules, Isatuximab, Dexamethasone Tablets 2 mg, Revlimid 15 mg hard capsules, Isatuximab, VELCADE 1 mg powder for solution for injection, Revlimid 10 mg hard capsules

    Ningbo Cancer Hospital

    Newly diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  3. Revumenib

    Syndax Pharmaceuticals

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  4. Rezvilutamide

    Nanjing Zenshine Pharmaceuticals

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  5. Rezvilutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Metastatic Hormone-Sensitive Prostate Cancer

    phase 2 small molecule active

    1 trial

  6. Rilvegostomig, Rilvegostomig

    AstraZeneca AB

    Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, stage III unresectable Non-small Cell Lung Cancer (Protocol Parts A-B), stage IV Non-small Cell Lung Cancer (Protocol Parts A-E).

    phase 2 small molecule active

    1 trial

  7. Rubraca 300 mg film-coated tablets, Rubraca 200 mg film-coated tablets, BEVACIZUMAB, Rubraca 250 mg film-coated tablets, CARBOPLATIN, PACLITAXEL

    Fondazione Telethon ETS

    Advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer.

    phase 2 small molecule active

    1 trial

  8. Rucaparib

    United Therapeutics Europe Ltd

    Cervical Cancer

    phase 2 small molecule terminated

    1 trial

  9. S-1

    United Therapeutics Europe Ltd

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    2 trials

  10. S-1

    United Therapeutics Europe Ltd

    Locally Advanced or Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  11. S095018

    Regeneron UK Limited

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  12. S095029/Sym025, LIBTAYO 350 mg concentrate for solution for infusion., S095018/Sym023, S095024/Sym024

    The George Institute

    Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where participants are not candidates for surgical resection and/or definitive chemoradiation, or - Metastatic NSCLC

    phase 2 small molecule active

    1 trial

  13. SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy in patients with early triple-negative breast cancer (TNBC). An open-label randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK

    The George Institute

    Early triple-negative breast cancer (TNBC)

    phase 2 other active

    1 trial

  14. SAR439859, Verzenios 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, Verzenios 150 mg film-coated tablets, IBRANCE 75 mg hard capsules, Verzenios 50 mg film-coated tablets, IBRANCE 100 mg hard capsules

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  15. SELUMETINIB, CASODEX 50 mg compresse rivestite con film, OLAPARIB

    Istituto Gentili S.r.l.

    Metastatic breast cancer

    phase 2 small molecule active

    1 trial

  16. SG+I

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    TNBC, Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  17. SHR-1701 Combined With Fluazopalil

    Hunan Province Tumor Hospital

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. SI-B001

    Sichuan Baili Pharmaceutical Co.,

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. SILIMARIN 200 mg compresse rivestite, Kisqali 200 mg film-coated tablets

    Fondazione Telethon ETS

    hormone receptor positive, HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  20. SILTUXIMAB, Tarlatamab, Tarlatamab

    Amgen

    Small Cell Lung Cancer (SCLC)

    phase 2 small molecule active

    1 trial

  21. SODIUM CHLORIDE, LIDOCAINE HYDROCHLORIDE MONOHYDRATE

    The George Institute

    Colon cancer

    phase 2 small molecule active

    1 trial

  22. SOTORASIB

    Amgen

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  23. SRF617

    Arcus Biosciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  24. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources